Others used blocking mAbs to CCR5 or even one of its three ligands, CCL5, to inhibit metastasis and improve the survival of tumor-bearing mice (118, 119) and also enhance anti-PD1 efficacy in gastric cancer (120). This evidence concerns the gene CCR5 and neoplasm.